Skip to main content
  1. Right Decisions
  2. Back
  3. Dermatology pathways
  4. Hidradenitis suppurativa

Hidradenitis suppurativa

Centre for Sustainable Delivery logo with the word Dermatology added at the base of the Logo
Warning

Not all treatment options may be listed in this guidance. Please refer to local formulary for a complete list.

Background

Hidradenitis Suppurativa (HS) is a painful, long term skin condition that causes skin abscesses and scarring on the skin. The exact cause of Hidradenitis Suppurativa is unknown, but it occurs near hair follicles where there are sweat glands, usually around the groin, bottom, breasts and armpits. It is thought to affect 1 in 100 people.

HS is common and often severe; many patients live with years of uncontrolled disease, absenteeism from work and poor mental health. (www.bad.org.uk/pils/hidradenitis-suppurativa)

Diagnostic delay is significant: international and UK data show average diagnostic delays of 7–10 years from symptom onset, causing preventable progression to irreversible scarring and higher-cost interventions. Early recognition and timely treatment reduce complications.
(https://pubmed.ncbi.nlm.nih.gov/38572195/)

This pathway recommends off label use of various medications. Please refer to local guidance on off label prescribing.

Pathway recommendations

Presentation
Hidradenitis Suppurativa (HS) presents as lumps, boils or tunnels of flexural skin. It is most commonly seen in the axillae, groins and under the breasts, but can also be found on the buttocks, natal cleft, apron fold and abdomen.

Consider diagnosis if there are typical lesions in a typical distribution and two or more episodes of lesions occurring over 6 months. Delayed diagnosis is common. If any tunnels are present then this indicates moderate to severe disease and requires secondary care review.

It is strongly associated with obesity and smoking and addressing these risk factors is an important part of management.

HS lesions:

Nodules
  • Inflamed lumps which can be painful

Abscesses
  • Larger, more swollen and fluctuant than nodules
  • Very painful
  • Will often burst discharging blood and pus

Tunnels/sinus tracts

  • Blind ended openings to the skins surface
  • Discharge pus
  • Tunnels represent scarring and are irreversible
  • Scarring causes sulci giving cerebriform or rope-like appearances

 

Comedones

  • Less common that other lesions and cause less morbidity
  • Can respond to acne type topical treatments e.g. retinoids

Treatment/therapy

Mild: Intermittent small numbers of inflammatory nodules and/or abscesses. Minimal scarring and no tunnels

Treatment:

  • Doxycycline 100mg od for 3 months (or Lymecycline 408mg od if intolerant of doxycycline)
  • Topical 1% clindamycin lotion
  • Antiseptic wash (e.g. Chlorhexidine)
  • Assess for metabolic syndrome
  • Assess pain, itch and wound management requirements
  • Assess mood

Lifestyle factors: smoking cessation, weight loss if overweight

Provide BAD patient information leaflet

Moderate to Severe: More frequent or constant nodules and/ or abscesses with scarring +/- tunnels

Refer to Dermatology

Treatment whilst awaiting secondary care review:

  • Doxycycline 100mg od for 3 months (or Lymecycline 408mg od if intolerant of doxycycline)
  • Topical 1% clindamycin lotion
  • Antiseptic wash (e.g. Chlorhexidine)
  • Consider rifampicin 300mg bd and clindamycin 300mg bd for 3 months if doxycycline ineffective
  • Consider off label use of metformin MR up-titrate to 1.5g daily
  • Consider off label use of spironolactone 50-100mg od for females if having cyclical flares
  • Assess for metabolic syndrome
  • Assess pain, itch and wound management requirements
  • Assess mood

Lifestyle factors: smoking cessation, weight loss if overweight

Provide BAD patient information leaflet

Treatment of acute flares (e.g. acutely inflamed abscess) regardless of disease severity

  • Consider co-amoxyclav 625mg tid for 7 days
  • If penicillin allergic consider clarithromycin or co-trimoxazole

Referral management
Manage mild disease in primary care initially and consider referral if poor response to treatment.
For moderate to severe disease, please refer to Dermatology and commence initial management as outlined

References and further resources

Editorial Information

Next review date: 01/07/2029

Author email(s): cfsdmppp@nhs.scot.